NING LI-GYN
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） (NCT07690332) | NING LI-GYN | 2026-07-20 |
Track NING LI-GYN automatically
Every clearance here is in the API, with alerts when new ones post.